Asymptomatic Neurosyphilis May Need Early Intervention in People Living with HIV
Syphilis, a sexually transmitted infection caused by Treponema pallidum, remains a global public health challenge with significant historical and clinical implications. Among people living with HIV (PLWH), syphilis coinfection is common due to overlapping transmission routes. A critical concern in this population is the heightened risk of neurosyphilis, a severe complication where T. pallidum invades the central nervous system (CNS). While neurosyphilis can manifest with neurological symptoms such as meningitis, stroke, cranial nerve dysfunction, or psychiatric changes, a substantial proportion of PLWH develop asymptomatic neurosyphilis. This condition lacks overt clinical signs but is characterized by cerebrospinal fluid (CSF) abnormalities, including pleocytosis, elevated protein levels, or reactive CSF Venereal Disease Research Laboratory (VDRL) tests. Left undiagnosed and untreated, asymptomatic neurosyphilis may lead to delayed neurological sequelae, treatment failure, or persistent CNS infection.
Epidemiology and Risk Factors
PLWH are disproportionately vulnerable to neurosyphilis, even during early or latent stages of syphilis. Studies report alarming rates of asymptomatic neurosyphilis in this population. For instance, a study of 46 PLWH undergoing lumbar puncture (LP) revealed asymptomatic neurosyphilis in 22% of cases during early infection. Another analysis of 117 PLWH with CSF abnormalities consistent with neurosyphilis found that 33% lacked neurological symptoms. Risk factors strongly associated with asymptomatic neurosyphilis include a CD4+ T-cell count <350 cells/μL, a serum VDRL titer ≥1:32, poor HIV virological control, and a history of recurrent syphilis. These markers highlight the interplay between HIV-induced immunosuppression and T. pallidum’s ability to evade detection and persist in the CNS.
Diagnostic Challenges and Current Guidelines
Diagnosing asymptomatic neurosyphilis requires CSF analysis via LP, as serological tests alone cannot confirm CNS involvement. However, clinical guidelines remain contentious. The U.S. Centers for Disease Control and Prevention (CDC) recommends LP only for PLWH exhibiting neurological symptoms, whereas European guidelines advocate broader criteria: CSF examination for all PLWH with serum VDRL titers ≥1:32 and CD4+ T-cell counts <350 cells/μL. This discrepancy underscores a critical gap in managing asymptomatic cases. Clinically, LP uptake is suboptimal; a Polish cohort reported that only 47.7% of eligible PLWH consented to LP, despite 82.6% of those tested confirming neurosyphilis. Reluctance to undergo invasive procedures, coupled with inconsistent guidelines, leaves many asymptomatic cases undetected, increasing the risk of long-term neurological damage.
Treatment Dilemmas and Emerging Evidence
Current syphilis treatment guidelines for PLWH lack consensus. The CDC and World Health Organization (WHO) recommend stage-based regimens: a single intramuscular dose of benzathine penicillin G (BPG) 2.4 million units (MU) for early syphilis and three weekly doses for late latent or neurosyphilis. However, emerging data suggest that standard regimens may be inadequate for PLWH due to impaired immunity and high rates of asymptomatic CNS involvement.
A UK retrospective study of 130 PLWH treated with a neuropenetrative regimen (intramuscular procaine penicillin 2.4 MU daily plus oral probenecid for 17 days) reported a 98% serological success rate, outperforming traditional BPG protocols. In contrast, a U.S. randomized trial found no significant difference in outcomes between single and three-dose BPG regimens in PLWH, aligning with CDC recommendations. These conflicting results underscore the complexity of treatment optimization. Notably, BPG has poor CNS penetration, raising concerns about its efficacy in eradicating T. pallidum from the CNS. Alternative agents like ceftriaxone, which achieves therapeutic CSF levels, have shown promise in pilot studies but require further validation.
Complications and Follow-Up Considerations
The Jarisch-Herxheimer reaction (JHR), an inflammatory response to treponemal lysis, occurs more frequently in PLWH post-treatment. Studies report higher JHR incidence in HIV-coinfected individuals, necessitating vigilant monitoring. Additionally, treatment failure or reinfection may necessitate repeated BPG courses, particularly in patients with persistent serological non-response. Long-term follow-up is critical, as neuroimaging studies reveal that 42.1% of treated neurosyphilis patients develop cerebral infarctions, 47.4% exhibit brain atrophy, and 15.8% show white matter demyelination, emphasizing the consequences of delayed or inadequate intervention.
Future Directions and Clinical Implications
Prospective studies with robust follow-up periods are urgently needed to clarify optimal treatment regimens for PLWH. Key priorities include:
- Expanding LP Criteria: Integrating CD4+ T-cell counts, VDRL titers, and HIV virological status into LP eligibility criteria to improve asymptomatic neurosyphilis detection.
- Evaluating Alternative Therapies: Assessing ceftriaxone and prolonged penicillin regimens for enhanced CNS penetration.
- Standardizing Guidelines: Reconciling discrepancies between U.S. and European recommendations to establish unified, evidence-based protocols.
- Improving Patient Adherence: Addressing barriers to LP acceptance and treatment adherence through patient education and less invasive diagnostic tools.
Conclusion
Asymptomatic neurosyphilis in PLWH represents a stealthy yet grave threat, demanding heightened clinical suspicion and proactive management. Current diagnostic and therapeutic frameworks must evolve to address the unique challenges posed by HIV coinfection, prioritizing early detection through expanded LP criteria and tailored antimicrobial regimens. Without such measures, the burden of irreversible neurological damage in this vulnerable population will persist.
doi: 10.1097/cm9.0000000000001143
Was this helpful?
0 / 0